J. G. MatiP. KenyaA. KunguD. GateiSuporn SilpisoronkosolTieng PardthaisongVirote SahapongChoti TheetranontBanpot BoosiriSupawat ChutivongsePramuan VirutmasenChansuda WongsrchanalaiSermsri SindhvanandaSuporn KoetsawangDaungdao RachawatAmom KoetsawangP. P. AnthonyDavid B. ThomasElizabeth A. NoonanRoberta M. RayKarin A. RosenblattJanet L. StanfordSusan HolckTimothy M.M. FarleyKarin A. RosenblattDavid B. ThomasChiang Mai UniversityChulalongkorn UniversityMahidol UniversityN. and East Devon Health AuthorityFred Hutchinson Cancer Research CenterOrganisation Mondiale de la Sante2018-08-102018-08-101991-01-01International Journal of Cancer. Vol.49, No.2 (1991), 182-18510970215002071362-s2.0-0025815286https://repository.li.mahidol.ac.th/handle/20.500.14594/22015A hospital‐based case‐control study was conducted to assess the possible relationship between use of depot‐medroxy‐progesterone acetate (DMPA), an injectable progestational contraceptive, and the development of liver cancer in 2 developing countries where hepatitis B is endemic. Information about prior DMPA use and potential confounders was ascertained during personal interviews with 71 cases and 530 controls from 3 hospitals in Thailand and 1 hospital in Kenya. No significant association between liver cancer and DMPA use was observed in Kenya (RR = 1.64, 95% CI = 0.4‐0.6) or Thailand (RR = 0.33, 95% CI = 0.1‐1.O). No consistent changes in risk were observed with duration of use, time since last use, or time since first use. No significant associations were observed between DMPA use and risks of either hepatocellular carcinoma or cholangiocarcinoma. These findings suggest that risk of liver cancer in areas where hepatitis B is endemic is not appreciably altered by the use of DMPA. Copyright © 1991 Wiley‐Liss, Inc., A Wiley CompanyMahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1002/ijc.2910490206